Lakefront Biotherapeutics buys back €3.32M in shares

At market close on October 9, 2026, Lakefront held 1,877,353 of its own ordinary shares.

Rhea-AI Filing Summary

Lakefront Biotherapeutics NV repurchased 126,322 ordinary shares between October 5 and October 9, 2026, within the repurchase program announced June 9, 2026. The average price paid was €26.26 per share, for a total of €3,317,407.94; reported purchase prices ranged from €25.78 to €26.78 per share.

Filing Explained

At the October 9, 2026 market close, Lakefront reported holding 1,877,353 of its own ordinary shares, establishing its dated own-share position. This is the reported holdings figure, distinct from the 126,322 shares bought during the week.

Key Figures

Ordinary shares repurchased: 126,322 shares Average price paid: €26.26 per share Total paid: €3,317,407.94 +3 more

6 metrics

Ordinary shares repurchased 126,322 shares Between October 5 and October 9, 2026

Average price paid €26.26 per share Repurchases between October 5 and October 9, 2026

Total paid €3,317,407.94 Repurchases between October 5 and October 9, 2026

Lowest price paid €25.78 per share Repurchases between October 5 and October 9, 2026

Highest price paid €26.78 per share Repurchases between October 5 and October 9, 2026

Own ordinary shares held 1,877,353 shares As of market close on October 9, 2026

Key Terms

repurchase program, discretionary mandate, MTF, T-cell engager, +1 more

5 terms

repurchase program financial

"the repurchase program announced on June 9, 2026"

A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.

discretionary mandate financial

"via a discretionary mandate to an independent financial intermediary"

MTF financial

"Market/MTF"

A multilateral trading facility (MTF) is a regulated electronic marketplace where multiple buyers and sellers can trade stocks, bonds or other securities through a central operator. Think of it as an alternative shopping mall for trades that can offer different prices, lower fees or faster matches than traditional exchanges. Investors care because MTFs influence where orders get filled, how easily assets can be bought or sold, and the prices and transparency available in the market.

T-cell engager medical

"a potential first-in-class and best-in-class BCMAxCD3 T-cell engager"

A T-cell engager is a type of medicine designed to help the body's immune system attack cancer cells more effectively. It works by acting like a bridge that brings immune cells (T-cells) close to cancer cells, prompting a targeted attack. For investors, T-cell engagers are significant because they represent innovative treatments that could lead to new growth opportunities in the healthcare and biotech sectors.

BCMAxCD3 T-cell engager medical

"BCMAxCD3 T-cell engager for autoimmune diseases"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LKFT shares did Lakefront repurchase, and what did they cost?

Lakefront Biotherapeutics NV repurchased 126,322 ordinary shares between October 5 and October 9, 2026, at an average price of €26.26 per share and a total of €3,317,407.94.

How many of its own shares did LKFT hold after the repurchases?

At market close on October 9, 2026, Lakefront held 1,877,353 of its own ordinary shares.

How did Lakefront execute the LKFT share repurchases?

Lakefront repurchased the shares via a discretionary mandate to an independent financial intermediary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 04:37 PM EDT Accepted by SEC EDGAR 10/13/2026 - 04:36 PM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On October 13, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated October 13, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Lakefront Biotherapeutics
		(Registrant)
Date: October 13, 2026		/s/ Ying Deng
		Ying Deng
		Authorized Officer

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between October 05, 2026 and October 09, 2026 it has repurchased 126,322 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchase	Market/MTF	Number of shares	Average price paid (€)	Total (€)	Lowest price paid (€)	Highest price paid (€)
10/5/2026	XAMS	20,641	26.14	539,466.98	25.78	26.50
10/5/2026	TQEX	442	26.01	11,497.92	25.90	26.04
10/5/2026	CEUX	2,656	25.97	68,975.52	25.82	26.22
10/5/2026	AQEU	174	25.88	4,503.12	25.88	25.88
10/6/2026	XAMS	20,421	26.40	539,130.74	25.94	26.64
10/6/2026	TQEX	1,383	26.54	36,708.97	26.20	26.64
10/6/2026	CEUX	2,620	26.51	69,458.30	26.42	26.64
10/6/2026	AQEU	679	26.59	18,051.55	26.44	26.64
10/7/2026	XAMS	22,325	26.15	583,776.43	25.86	26.54
10/7/2026	CEUX	2,566	26.16	67,136.05	25.90	26.48
10/7/2026	AQEU	506	26.18	13,246.17	26.00	26.50
10/8/2026	XAMS	22,557	26.20	591,027.24	25.82	26.78
10/8/2026	TQEX	150	26.27	3,940.01	26.24	26.34
10/8/2026	CEUX	2,158	26.27	56,690.44	26.20	26.36
10/8/2026	AQEU	817	26.20	21,408.91	26.20	26.22
10/9/2026	XAMS	21,498	26.40	567,643.94	26.18	26.66
10/9/2026	TQEX	592	26.38	15,616.60	26.34	26.46
10/9/2026	CEUX	3,394	26.37	89,516.07	26.34	26.44
10/9/2026	AQEU	743	26.40	19,612.97	26.34	26.46
Total		126,322	26.26	3,317,407.94	25.78	26.78

As of market close on October 9, 2026, Lakefront holds 1,877,353 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 39.2 KB